---
document_datetime: 2025-12-02 04:55:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/abiraterone-mylan.html
document_name: abiraterone-mylan.html
version: success
processing_time: 0.1276447
conversion_datetime: 2025-12-28 19:40:05.612526
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Abiraterone Mylan

[RSS](/en/individual-human-medicine.xml/67454)

##### Authorised

This medicine is authorised for use in the European Union

abiraterone acetate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Abiraterone Mylan](#news-on)
- [More information on Abiraterone Mylan](#more-information-on-abiraterone-mylan-1617)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Abiraterone Mylan is a cancer medicine used to treat men with metastatic prostate cancer. This is cancer that affects the prostate gland (a gland of the male reproductive system). It is used when the cancer has spread to other parts of the body (metastatic).

Abiraterone Mylan is used together with prednisone or prednisolone (anti-inflammatory medicines):

- when the cancer is newly diagnosed, high risk and sensitive to hormones; Abiraterone Mylan is then used in combination with a treatment called androgen deprivation therapy;
- when medical castration (using medicines to stop the production of male hormones) with androgen deprivation therapy has not worked or no longer works in men who have either no symptoms or only mild symptoms of the disease, and who do not yet need chemotherapy (cancer medicines);
- when medical or surgical castration and chemotherapy containing docetaxel have not worked or no longer work.

Abiraterone Mylan contains the active substance abiraterone acetate and is a 'generic medicine'. This means that Abiraterone Mylan contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Zytiga.

Expand section

Collapse section

## How is Abiraterone Mylan used?

Abiraterone Mylan is available as tablets and can only be obtained with a prescription. The recommended dose is 1,000 mg taken once a day on an empty stomach. This means that the patient should wait at least two hours after eating before taking the medicine and must not eat for at least one hour after taking the medicine. If the patient develops liver problems, treatment should be stopped. Treatment may be resumed at a reduced dose if the liver function returns to normal.

For more information about using Abiraterone Mylan, see the package leaflet or contact your doctor or pharmacist.

## How does Abiraterone Mylan work?

The active substance in Abiraterone Mylan, abiraterone acetate, is changed in the body to abiraterone which stops the body producing testosterone, a male hormone. Abiraterone does this by blocking an enzyme called CYP17 found in the testes and elsewhere in the body. Because the cancer needs a supply of testosterone to survive and grow, by reducing the production of testosterone, Abiraterone Mylan can slow the growth of the prostate cancer.

## How has Abiraterone Mylan been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Zytiga, and do not need to be repeated for Abiraterone Mylan.

As for every medicine, the company provided data on the quality of Abiraterone Mylan. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Abiraterone Mylan?

Because Abiraterone Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Abiraterone Mylan authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Abiraterone Mylan has been shown to have comparable quality and to be bioequivalent to Zytiga. Therefore, the Agency's view was that, as for Zytiga, the benefits of Abiraterone Mylan outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Abiraterone Mylan?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Abiraterone Mylan have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Abiraterone Mylan are continuously monitored. Side effects reported with Abiraterone Mylan are carefully evaluated and any necessary action taken to protect patients.

## Other information about Abiraterone Mylan

Abiraterone Mylan received a marketing authorisation valid throughout the EU on 20 August 2021.

Abiraterone Mylan : EPAR - Medicine overview

Reference Number: EMA/395446/2021

English (EN) (166.84 KB - PDF)

**First published:** 26/08/2021

[View](/en/documents/overview/abiraterone-mylan-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-216)

български (BG) (188.37 KB - PDF)

**First published:**

26/08/2021

[View](/bg/documents/overview/abiraterone-mylan-epar-medicine-overview_bg.pdf)

español (ES) (166.9 KB - PDF)

**First published:**

26/08/2021

[View](/es/documents/overview/abiraterone-mylan-epar-medicine-overview_es.pdf)

čeština (CS) (184.88 KB - PDF)

**First published:**

26/08/2021

[View](/cs/documents/overview/abiraterone-mylan-epar-medicine-overview_cs.pdf)

dansk (DA) (165.04 KB - PDF)

**First published:**

26/08/2021

[View](/da/documents/overview/abiraterone-mylan-epar-medicine-overview_da.pdf)

Deutsch (DE) (171.08 KB - PDF)

**First published:**

26/08/2021

[View](/de/documents/overview/abiraterone-mylan-epar-medicine-overview_de.pdf)

eesti keel (ET) (153.64 KB - PDF)

**First published:**

26/08/2021

[View](/et/documents/overview/abiraterone-mylan-epar-medicine-overview_et.pdf)

ελληνικά (EL) (189.16 KB - PDF)

**First published:**

26/08/2021

[View](/el/documents/overview/abiraterone-mylan-epar-medicine-overview_el.pdf)

français (FR) (167.69 KB - PDF)

**First published:**

26/08/2021

[View](/fr/documents/overview/abiraterone-mylan-epar-medicine-overview_fr.pdf)

hrvatski (HR) (183.17 KB - PDF)

**First published:**

26/08/2021

[View](/hr/documents/overview/abiraterone-mylan-epar-medicine-overview_hr.pdf)

italiano (IT) (164.52 KB - PDF)

**First published:**

26/08/2021

[View](/it/documents/overview/abiraterone-mylan-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (203.68 KB - PDF)

**First published:**

26/08/2021

[View](/lv/documents/overview/abiraterone-mylan-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (175.54 KB - PDF)

**First published:**

26/08/2021

[View](/lt/documents/overview/abiraterone-mylan-epar-medicine-overview_lt.pdf)

magyar (HU) (185.32 KB - PDF)

**First published:**

26/08/2021

[View](/hu/documents/overview/abiraterone-mylan-epar-medicine-overview_hu.pdf)

Malti (MT) (190.12 KB - PDF)

**First published:**

26/08/2021

[View](/mt/documents/overview/abiraterone-mylan-epar-medicine-overview_mt.pdf)

Nederlands (NL) (158.31 KB - PDF)

**First published:**

26/08/2021

[View](/nl/documents/overview/abiraterone-mylan-epar-medicine-overview_nl.pdf)

polski (PL) (189.44 KB - PDF)

**First published:**

26/08/2021

[View](/pl/documents/overview/abiraterone-mylan-epar-medicine-overview_pl.pdf)

português (PT) (166.24 KB - PDF)

**First published:**

26/08/2021

[View](/pt/documents/overview/abiraterone-mylan-epar-medicine-overview_pt.pdf)

română (RO) (192.01 KB - PDF)

**First published:**

26/08/2021

[View](/ro/documents/overview/abiraterone-mylan-epar-medicine-overview_ro.pdf)

slovenčina (SK) (186.89 KB - PDF)

**First published:**

26/08/2021

[View](/sk/documents/overview/abiraterone-mylan-epar-medicine-overview_sk.pdf)

slovenščina (SL) (183.99 KB - PDF)

**First published:**

26/08/2021

[View](/sl/documents/overview/abiraterone-mylan-epar-medicine-overview_sl.pdf)

Suomi (FI) (162.62 KB - PDF)

**First published:**

26/08/2021

[View](/fi/documents/overview/abiraterone-mylan-epar-medicine-overview_fi.pdf)

svenska (SV) (164.39 KB - PDF)

**First published:**

26/08/2021

[View](/sv/documents/overview/abiraterone-mylan-epar-medicine-overview_sv.pdf)

Abiraterone Mylan : EPAR - Risk-management-plan summary

English (EN) (109.04 KB - PDF)

**First published:** 26/08/2021

[View](/en/documents/rmp-summary/abiraterone-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Abiraterone Mylan : EPAR - Product information

English (EN) (1001.86 KB - PDF)

**First published:** 26/08/2021

**Last updated:** 06/01/2025

[View](/en/documents/product-information/abiraterone-mylan-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-170)

български (BG) (1.06 MB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/bg/documents/product-information/abiraterone-mylan-epar-product-information_bg.pdf)

español (ES) (605.32 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/es/documents/product-information/abiraterone-mylan-epar-product-information_es.pdf)

čeština (CS) (1012.18 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/cs/documents/product-information/abiraterone-mylan-epar-product-information_cs.pdf)

dansk (DA) (742.81 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/da/documents/product-information/abiraterone-mylan-epar-product-information_da.pdf)

Deutsch (DE) (607.17 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/de/documents/product-information/abiraterone-mylan-epar-product-information_de.pdf)

eesti keel (ET) (690.46 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/et/documents/product-information/abiraterone-mylan-epar-product-information_et.pdf)

ελληνικά (EL) (850.9 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/el/documents/product-information/abiraterone-mylan-epar-product-information_el.pdf)

français (FR) (708.02 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/fr/documents/product-information/abiraterone-mylan-epar-product-information_fr.pdf)

hrvatski (HR) (785.03 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/hr/documents/product-information/abiraterone-mylan-epar-product-information_hr.pdf)

íslenska (IS) (743.61 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/is/documents/product-information/abiraterone-mylan-epar-product-information_is.pdf)

italiano (IT) (737.74 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/it/documents/product-information/abiraterone-mylan-epar-product-information_it.pdf)

latviešu valoda (LV) (1.02 MB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/lv/documents/product-information/abiraterone-mylan-epar-product-information_lv.pdf)

lietuvių kalba (LT) (889.49 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/lt/documents/product-information/abiraterone-mylan-epar-product-information_lt.pdf)

magyar (HU) (755.92 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/hu/documents/product-information/abiraterone-mylan-epar-product-information_hu.pdf)

Malti (MT) (949.69 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/mt/documents/product-information/abiraterone-mylan-epar-product-information_mt.pdf)

Nederlands (NL) (654.91 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/nl/documents/product-information/abiraterone-mylan-epar-product-information_nl.pdf)

norsk (NO) (751.8 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/no/documents/product-information/abiraterone-mylan-epar-product-information_no.pdf)

polski (PL) (698.2 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/pl/documents/product-information/abiraterone-mylan-epar-product-information_pl.pdf)

português (PT) (646.49 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/pt/documents/product-information/abiraterone-mylan-epar-product-information_pt.pdf)

română (RO) (835.73 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/ro/documents/product-information/abiraterone-mylan-epar-product-information_ro.pdf)

slovenčina (SK) (835.52 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/sk/documents/product-information/abiraterone-mylan-epar-product-information_sk.pdf)

slovenščina (SL) (888.06 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/sl/documents/product-information/abiraterone-mylan-epar-product-information_sl.pdf)

Suomi (FI) (837.74 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/fi/documents/product-information/abiraterone-mylan-epar-product-information_fi.pdf)

svenska (SV) (1.2 MB - PDF)

**First published:**

26/08/2021

**Last updated:**

06/01/2025

[View](/sv/documents/product-information/abiraterone-mylan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0011 12/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Abiraterone Mylan : EPAR - All authorised presentations

English (EN) (57.77 KB - PDF)

**First published:** 26/08/2021

**Last updated:** 17/03/2023

[View](/en/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-617)

български (BG) (70.48 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/bg/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (53.16 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/es/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (65.27 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/cs/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (79.17 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/da/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (56.82 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/de/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (54.49 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/et/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (73.79 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/el/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (54.67 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/fr/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (70.76 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/hr/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (51.17 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/is/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (56.56 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/it/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (74.23 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/lv/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (74.93 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/lt/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (73.8 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/hu/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (74.16 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/mt/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (53.24 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/nl/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (52.82 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/no/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (27.87 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/pl/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (40.21 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/pt/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (22.6 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/ro/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (72.06 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/sk/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (71.02 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/sl/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (52.39 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/fi/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (50.93 KB - PDF)

**First published:**

26/08/2021

**Last updated:**

17/03/2023

[View](/sv/documents/all-authorised-presentations/abiraterone-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Abiraterone Mylan Active substance abiraterone acetate International non-proprietary name (INN) or common name abiraterone acetate Therapeutic area (MeSH) Prostatic Neoplasms Anatomical therapeutic chemical (ATC) code L02BX03

### Pharmacotherapeutic group

- Endocrine therapy
- Other hormone antagonists and related agents

### Therapeutic indication

Abiraterone Mylan is indicated with prednisone or prednisolone for:

- the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).
- the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
- the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

## Authorisation details

EMA product number EMEA/H/C/005368

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan Pharmaceuticals Limited

Damastown Industrial Park

Opinion adopted 24/06/2021 Marketing authorisation issued 20/08/2021 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Abiraterone Mylan : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (155.3 KB - PDF)

**First published:** 16/02/2022

**Last updated:** 06/01/2025

[View](/en/documents/procedural-steps-after/abiraterone-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Abiraterone Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/444189/2021

English (EN) (889.81 KB - PDF)

**First published:** 26/08/2021

[View](/en/documents/assessment-report/abiraterone-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Abiraterone Mylan

Adopted

Reference Number: EMA/CHMP/313865/2021

English (EN) (160.6 KB - PDF)

**First published:** 25/06/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-abiraterone-mylan_en.pdf)

#### News on Abiraterone Mylan

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021) 25/06/2021

#### More information on Abiraterone Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

**This page was last updated on** 06/01/2025

## Share this page

[Back to top](#main-content)